We've entered into this agreement for two purposes. The first is to raise capital for opportunistic -- opportunistic acquisitions and partnerships, and the second is to increase the liquidity of our stock. We currently intend to use the net proceeds we received from this offering to fund potential acquisitions, further development of our products, services and technology pipeline and clinical studies expand our sales force and for general corporate purposes. Zachary Fleming At the end of 2022, we had a tota ...